Breaking News Briefs
Interim Results for CheckMate-743 Positive for Combination Nivolumab/Ipilimumab in Previously Untreated MPM
April 20, 2020—Based on a pre-specified interim analysis conducted by an independent Data...
Changing E-Cigarette Technology Leads to Increased Complexity and Confusion—IASLC Statement Aims for Clarity
Posted: November 12, 2019
Dr. Matthew Steliga, chair of the IASLC Tobacco Control and Smoking Cessation Committee and thoracic surgeon and head of the Tobacco...
Breaking News Briefs
Nivolumab in the News
The dosing schedule for nivolumab now includes a flat dose of 480 mg infused every 4 weeks (Q4W) for a majority...
Breaking News Briefs
Tumors with high TMB responded well to combination in large patient population.
By now the results of the phase III CheckMate-227 study are known...
Breaking News Briefs
The FoundationOne CDx (F1CDx) test received full U.S. Food and Drug Administration (FDA) approval. F1CDx is the first breakthrough-designated, next-generation sequencing–based in vitro diagnostic...
Breaking News Briefs
• Alectinib (Alecensa) received full FDA approval for the first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as determined by...
Breaking News Briefs
• Alectinib received FDA priority review designation for first-line treatment of patients with ALK-positive, locally advanced or metastatic NSCLC. The supplemental new drug application...
Breaking News Briefs
• Dabrafenib and trametidnib (Tafinlar and Mekinist) received FDA approval for use in combination for patients with metastatic non-small cell lung cancer (NSCLC) with...
Breaking News Briefs
• Pembrolizumab (Keytruda) received FDA approval for use in combination with pemetrexed and carboplatin for the first-line treatment of patients with metastatic nonsquamous NSCLC,...
Breaking News Briefs
• The global, randomized phase III ALEX study was announced to have met its primary endpoint, demonstrating that alectinib (Alecensa), as an initial (first-line)...
